Resource Center
Resource Center
This webinar, the first in a two-part series, guides usage of CHAI’s HIV New Product Introduction Toolkit. The toolkit provides Ministries of Health and implementing partners with the tools necessary to evaluate the adoption and introduction of new HIV products in their local context. The webinar also provides an overview of the CHAI ARV Phase-In/Phase-Out...
Read moreThe HIV/AIDS community received good news ahead of the 2017 International AIDS Society (IAS) meeting in Paris: for the first time ever, more than 50 percent of people living with HIV were receiving antiretroviral therapy (ART) at the end of 2016 and AIDS-related deaths have halved since 2005. If this trend continues, the world will...
Read moreCHAI’s ARV Market Report provides a global perspective on the ARV marketplace in low- and middle-income countries in 2016 and outlines CHAI’s expectations on how the market will evolve over the next five years. Read the report here: 2017 ARV Market Report
Read moreNegotiated pricing agreements have lowered costs and will improve access to quality treatment for people living with HIV New York – A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries...
Read moreNational HIV treatment programs are preparing for big shifts in their national treatment guidelines and patient regimens. The World Health Organization’s (WHO) 2016 guidelines included a number of antiretroviral (ARV) medications that are more effective, tolerable and affordable (some of which are now available), in addition to optimal pediatric formulations which improve upon limited treatment...
Read moreLesotho is a small, landlocked country surrounded by South Africa with a population of about 2 million people. It also has the second highest prevalence of HIV in the world, with 23 percent of the population infected. This high HIV prevalence is a key contributing factor in Lesotho having one of the lowest life expectancies...
Read moreUntil recently, many low- and middle-income countries were not able to provide HIV treatment to all patients due to the high cost of medication and treatment was reserved for only the sickest individuals. Decisions about whether or not to initiate patients on lifesaving antiretroviral therapy (ART) were often based on how far a patient’s disease...
Read moreCD4 cell count is an important diagnostic test to manage HIV-positive patients in low- and middle-income countries. CD4 testing is used to prioritize patients for treatment in settings where treatment is not accessible to all, monitor patients on treatment where viral load testing is not available, and monitor and manage patients with advanced HIV disease...
Read moreSince 2002, CHAI has worked to increase access to HIV drugs and diagnostics in the developing world with the transformational goal of saving lives. Through collaboration with a broad coalition of partners, the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers, and Children (IATT) has helped support the...
Read moreCHAI’s first-ever HIV Mid-Year Market Memo is an informational brief that covers the latest trends in the HIV space since the publication of CHAI’s annual ARV Market Report in October 2016. See the HIV Mid-Year Market Memo here. See the 2016 ARV Market Report here.
Read more